Literature DB >> 8959296

Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients.

B N van Berckel1, R Hijman, J A van der Linden, H G Westenberg, J M van Ree, R S Kahn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8959296     DOI： 10.1016/S0006-3223(96)00311-3

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  15 in total

1.  Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.

Authors:  Surendra P Singh; Vidhi Singh
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

Review 2.  Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine.

Authors:  Stefan G Hofmann; Mark H Pollack; Michael W Otto
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

Review 3.  D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia.

Authors:  Donald C Goff
Journal:  Schizophr Bull       Date:  2012-02-23       Impact factor: 9.306

Review 4.  The potential role of lamotrigine in schizophrenia.

Authors:  Charles H Large; Elizabeth L Webster; Donald C Goff
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

5.  A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients.

Authors:  Donald C Goff; Lawrence Herz; Thomas Posever; Vivian Shih; Guochuan Tsai; David C Henderson; Oliver Freudenreich; A Eden Evins; Iftah Yovel; Hui Zhang; David Schoenfeld
Journal:  Psychopharmacology (Berl)       Date:  2004-10-21       Impact factor: 4.530

Review 6.  Glutamate receptor genes: susceptibility factors in schizophrenia and depressive disorders?

Authors:  Hans H Schiffer
Journal:  Mol Neurobiol       Date:  2002-04       Impact factor: 5.590

Review 7.  The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia.

Authors:  Joseph T Coyle; Guochuan Tsai
Journal:  Psychopharmacology (Berl)       Date:  2003-11-25       Impact factor: 4.530

8.  Treatment of Comorbid Tuberculosis and Depression.

Authors:  Adam J. Trenton; Glenn W. Currier
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-12

Review 9.  Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.

Authors:  Seong S Shim; Michael D Hammonds; Baik S Kee
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-09-27       Impact factor: 5.270

10.  Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.

Authors:  Christine E Marx; Richard S E Keefe; Robert W Buchanan; Robert M Hamer; Jason D Kilts; Daniel W Bradford; Jennifer L Strauss; Jennifer C Naylor; Victoria M Payne; Jeffrey A Lieberman; Adam J Savitz; Linda A Leimone; Lawrence Dunn; Patrizia Porcu; A Leslie Morrow; Lawrence J Shampine
Journal:  Neuropsychopharmacology       Date:  2009-04-01       Impact factor: 7.853
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.